您的位置: 首页 > 农业专利 > 详情页

CONTRÔLE THÉRAPEUTIQUE AMÉLIORÉ DE FORMES HÉTÉRODIMÈRES ET À CHAÎNE UNIQUE DE L'INTERLEUKINE-12
专利权人:
Intrexon Corporation
发明人:
申请号:
EP15844248.3
公开号:
EP3197911A4
申请日:
2015.09.21
申请国别(地区):
EP
年份:
2018
代理人:
摘要:
The present invention relates to modified forms of IL-12. These modified forms of IL-12 may be engineered to have a shortened in vivo half-life compared and/or enhanced localization of biological effects compared to that of corresponding non-modified form of IL-12. Short half-life and membrane bound forms of IL-12 may provide greater therapeutic control for in vivo therapeutic delivery, in particular when used in combination with ligand inducible delivery of IL-12. Modified forms of IL-12 engineered to have shortened in vivo half-life and/or enhanced localization of biological effects include heterodimeric p35/p40, single chain and membrane bound forms of IL-12 wherein a naturally occurring IL-12 amino acid sequence is genetically modified to enhance susceptibility of the IL-12 molecule to in vivo proteolytic degradation.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/
相关发明人

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充